- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Mankind Pharma Limited — Updates, 03-02-2026: Press Release
03-02-2026 | 04:19 pm
03-02-2026 | 04:19 pm
Mankind Pharma reported Q3FY26 revenue up 11.5% YoY to 3,567 Cr, with Adj. EBITDA margin at 25.9%. Growth was driven by domestic pharma and BSV consolidation. Chronic share increased to 39.3%, with robust cardiac and anti-diabetes growth, while OTC regained momentum.
No comments yet. Be the first to comment!